<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02420639</url>
  </required_header>
  <id_info>
    <org_study_id>ACT TBI-01</org_study_id>
    <nct_id>NCT02420639</nct_id>
  </id_info>
  <brief_title>Prospective, Interventional Study Evaluating the Feasibility and Safety of the Esophageal Cooling Device</brief_title>
  <official_title>Prospective, Interventional Study Evaluating the Feasibility and Safety of the Esophageal Cooling Device in 15 Patients Suffering From Traumatic Brain Injury and Treated With Targeted Temperature Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Advanced Cooling Therapy, Inc., d/b/a Attune Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dnipropetrovsk State Medical Academy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Advanced Cooling Therapy, Inc., d/b/a Attune Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this prospective, interventional study is to assess the feasibility and safety of&#xD;
      the Esophageal Cooling Device in patients from suffering from traumatic brain injury who the&#xD;
      treating physician is treating with targeted temperature management. Comparison of outcomes&#xD;
      will be made to historical controls. The primary outcome is the feasibility of inducing,&#xD;
      maintaining, and rewarming patients from targeted temperature management using the Esophageal&#xD;
      Cooling Device (cooling rate, rewarming rate, and the percent of time within goal temperature&#xD;
      during the goal-temperature maintenance period). Evaluation of adverse events (including&#xD;
      cardiac arrhythmias, severe bradycardia, myocardial infarction/re-infarction, dysphagia,&#xD;
      odynophagia, aspiration pneumonia, non-aspiration pneumonia, reflux, esophageal injury, and&#xD;
      esophagitis) will be closely monitored during the whole period of targeted temperature&#xD;
      management (secondary endpoint).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Controlling patient's body temperature, and in particular, reducing body temperature in a&#xD;
      treatment referred to as targeted temperature management, has been shown to improve outcomes&#xD;
      for many conditions, including neonatal hypoxic ischemic encephalopathy, cardiac arrest, and&#xD;
      traumatic brain injury. However, available modalities for inducing targeted temperature&#xD;
      management have a number of technical, logistical, and financial barriers. The Esophageal&#xD;
      Cooling Device is a multi-chambered silicone tube placed in the esophagus that provides a&#xD;
      highly efficient heat transfer to or from a patient.&#xD;
&#xD;
      Traumatic brain injury (TBI) is a major cause of death and severe disability throughout the&#xD;
      world. Current methods of traumatic brain injury treatment include reduction of brain&#xD;
      swelling and edema, both by surgical means, as well as by reduction of temperature and&#xD;
      avoidance of fever. Methods used to reduce temperature and control fever include surface&#xD;
      devices, such as ice packs and water circulating blankets, and intravascular catheters, which&#xD;
      are placed into a blood vessel.&#xD;
&#xD;
      The esophagus is in close proximity to blood flow from the heart and great vessels, and the&#xD;
      Esophageal Cooling Device (ECD) is designed to take advantage of this heat exchange&#xD;
      environment. The ECD's ability to decompress the stomach and avoid distention of the&#xD;
      esophagus away from the device ensures good contact with the esophageal mucosa, and thus&#xD;
      maximizes heat transfer from the patient. The ECD replaces the standard gastric tube which is&#xD;
      placed in the target patient population as a routine standard of care, is made of standard&#xD;
      medical-grade silicone, and is generally similar in size and shape to the gastric tubes&#xD;
      currently used. Initial mathematical, animal, and human data have shown strong support for&#xD;
      the efficacy and safety of the ECD.&#xD;
&#xD;
      The aim of this prospective, interventional study is to assess the feasibility and safety of&#xD;
      the Esophageal Cooling Device in patients from suffering from traumatic brain injury who the&#xD;
      treating physician is treating with targeted temperature management. Comparison of outcomes&#xD;
      will be made to historical controls. The primary outcome is the feasibility of inducing,&#xD;
      maintaining, and rewarming patients from targeted temperature management using the Esophageal&#xD;
      Cooling Device (cooling rate, rewarming rate, and the percent of time within goal temperature&#xD;
      during the goal-temperature maintenance period). Evaluation of adverse events (including&#xD;
      cardiac arrhythmias, severe bradycardia, myocardial infarction/re-infarction, dysphagia,&#xD;
      odynophagia, aspiration pneumonia, non-aspiration pneumonia, reflux, esophageal injury, and&#xD;
      esophagitis) will be closely monitored during the whole period of targeted temperature&#xD;
      management (secondary endpoint).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Initiation of Temperature Management</measure>
    <time_frame>30 days</time_frame>
    <description>Time to initiation of targeted temperature management, as measured from the time a decision is made to begin targeted temperature management, to the time the esophageal cooling device is in place.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of Performance Outcomes</measure>
    <time_frame>36 hours</time_frame>
    <description>Secondary performance outcomes include the feasibility of inducing, maintaining, and rewarming patients from targeted temperature management using the Esophageal Cooling Device. Specifically, cooling rate, rewarming rate, and the percent of time during the goal- temperature maintenance period within 1°C of goal temperature (typically 33°C, but with some centers using anywhere from 32°C to 36°C) will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of Safety Outcomes</measure>
    <time_frame>Assessed over 36 hours of treatment and up to 30 days of follow-up.</time_frame>
    <description>Secondary safety outcomes include evaluation of adverse events including the following: cardiac arrhythmias, severe bradycardia, myocardial infarction/re-infarction, dysphagia, odynophagia, aspiration pneumonia, non-aspiration pneumonia, reflux, esophageal injury, and esophagitis.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The placement of the Esophageal Cooling Device will follow standard recommendations as per Instructions for Use. The Esophageal Cooling Device will be connected to the appropriate console (Meditherm III, Blanketrol II, or Blanketrol III).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Esophageal Cooling Device (ECD), manufactured by Advanced Cooling Therapy, Inc.</intervention_name>
    <description>Use of the Esophageal Cooling Device for control of patient temperature.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient population will consist of 15 patients suffering from traumatic brain injury,&#xD;
             in whom the treating clinician has determined that targeted temperature management&#xD;
             will be initiated.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with known esophageal deformity or evidence of esophageal trauma (for&#xD;
             example, known esophageal varices, cirrhosis, history of esophagectomy, previous&#xD;
             swallowing disorders, achalasia, etc.).&#xD;
&#xD;
          -  Patients with known ingestion of acidic or caustic poisons within the prior 24 hours.&#xD;
&#xD;
          -  Patients with less than 40 kg of body mass.&#xD;
&#xD;
          -  Patients known to be pregnant.&#xD;
&#xD;
          -  Terminal disease or &quot;do not resuscitate order&quot; that could lead to early-onset&#xD;
             therapeutic withdrawal.&#xD;
&#xD;
          -  Unstable hemodynamic conditions that could lead to multi-organ failure and early-onset&#xD;
             death.&#xD;
&#xD;
          -  Pre-existing severe conductive disorder requiring pacing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oleksandr Tsarev, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dnipropetrivsk State Medical Academy based on Dnipropetrivsk Regional Clinical Hospital n.a. Mechnikov, Department of Anesthesiology and Intencive Care Medicine, 14 Octoberskay sq., Dnipropetrivsk 49600, Ukraine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dnipropetrivsk State Medical Academy based on Dnipropetrivsk Regional Clinical Hospital</name>
      <address>
        <city>Dnipropetrovs'k</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ukraine</country>
  </location_countries>
  <reference>
    <citation>Arrich J, Holzer M, Havel C, Müllner M, Herkner H. Hypothermia for neuroprotection in adults after cardiopulmonary resuscitation. Cochrane Database Syst Rev. 2012 Sep 12;(9):CD004128. doi: 10.1002/14651858.CD004128.pub3. Review. Update in: Cochrane Database Syst Rev. 2016;2:CD004128.</citation>
    <PMID>22972067</PMID>
  </reference>
  <reference>
    <citation>Crossley S, Reid J, McLatchie R, Hayton J, Clark C, MacDougall M, Andrews PJ. A systematic review of therapeutic hypothermia for adult patients following traumatic brain injury. Crit Care. 2014 Apr 17;18(2):R75. doi: 10.1186/cc13835. Review.</citation>
    <PMID>24742169</PMID>
  </reference>
  <reference>
    <citation>Andrews PJ, Sinclair LH, Harris B, Baldwin MJ, Battison CG, Rhodes JK, Murray G, De Backer D; Eurotherm3235Trial collaborators. Study of therapeutic hypothermia (32 to 35°C) for intracranial pressure reduction after traumatic brain injury (the Eurotherm3235Trial): outcome of the pilot phase of the trial. Trials. 2013 Sep 3;14:277. doi: 10.1186/1745-6215-14-277.</citation>
    <PMID>24004918</PMID>
  </reference>
  <reference>
    <citation>Polderman KH. Induced hypothermia and fever control for prevention and treatment of neurological injuries. Lancet. 2008 Jun 7;371(9628):1955-69. doi: 10.1016/S0140-6736(08)60837-5. Review.</citation>
    <PMID>18539227</PMID>
  </reference>
  <reference>
    <citation>Badjatia N. Hyperthermia and fever control in brain injury. Crit Care Med. 2009 Jul;37(7 Suppl):S250-7. doi: 10.1097/CCM.0b013e3181aa5e8d. Review.</citation>
    <PMID>19535955</PMID>
  </reference>
  <reference>
    <citation>Kulstad E, Metzger AK, Courtney DM, Rees J, Shanley P, Matsuura T, McKnite S, Lurie K. Induction, maintenance, and reversal of therapeutic hypothermia with an esophageal heat transfer device. Resuscitation. 2013 Nov;84(11):1619-24. doi: 10.1016/j.resuscitation.2013.06.019. Epub 2013 Jul 1.</citation>
    <PMID>23827887</PMID>
  </reference>
  <reference>
    <citation>Markota A, Kit B, Fluher J, Sinkovič A. Use of an oesophageal heat transfer device in therapeutic hypothermia. Resuscitation. 2015 Apr;89:e1-2. doi: 10.1016/j.resuscitation.2015.01.032. Epub 2015 Feb 7.</citation>
    <PMID>25660954</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 13, 2015</study_first_submitted>
  <study_first_submitted_qc>April 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2015</study_first_posted>
  <results_first_submitted>January 11, 2021</results_first_submitted>
  <results_first_submitted_qc>August 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 2, 2021</results_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 8, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT02420639/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intervention</title>
          <description>The placement of the Esophageal Cooling Device will follow standard recommendations as per Instructions for Use. The Esophageal Cooling Device will be connected to the appropriate console (Meditherm III, Blanketrol II, or Blanketrol III).&#xD;
Esophageal Cooling Device (ECD), manufactured by Advanced Cooling Therapy, Inc.: Use of the Esophageal Cooling Device for control of patient temperature.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12">Study obtained 12 patients</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12">Total of 12 patients enrolled</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intervention</title>
          <description>The placement of the Esophageal Cooling Device will follow standard recommendations as per Instructions for Use. The Esophageal Cooling Device will be connected to the appropriate console (Meditherm III, Blanketrol II, or Blanketrol III).&#xD;
Esophageal Cooling Device (ECD), manufactured by Advanced Cooling Therapy, Inc.: Use of the Esophageal Cooling Device for control of patient temperature.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Ukraine</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.3" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Initiation of Temperature Management</title>
        <description>Time to initiation of targeted temperature management, as measured from the time a decision is made to begin targeted temperature management, to the time the esophageal cooling device is in place.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>The placement of the Esophageal Cooling Device will follow standard recommendations as per Instructions for Use. The Esophageal Cooling Device will be connected to the appropriate console (Meditherm III, Blanketrol II, or Blanketrol III).&#xD;
Esophageal Cooling Device (ECD), manufactured by Advanced Cooling Therapy, Inc.: Use of the Esophageal Cooling Device for control of patient temperature.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Initiation of Temperature Management</title>
          <description>Time to initiation of targeted temperature management, as measured from the time a decision is made to begin targeted temperature management, to the time the esophageal cooling device is in place.</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.83" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite of Performance Outcomes</title>
        <description>Secondary performance outcomes include the feasibility of inducing, maintaining, and rewarming patients from targeted temperature management using the Esophageal Cooling Device. Specifically, cooling rate, rewarming rate, and the percent of time during the goal- temperature maintenance period within 1°C of goal temperature (typically 33°C, but with some centers using anywhere from 32°C to 36°C) will be measured.</description>
        <time_frame>36 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite of Safety Outcomes</title>
        <description>Secondary safety outcomes include evaluation of adverse events including the following: cardiac arrhythmias, severe bradycardia, myocardial infarction/re-infarction, dysphagia, odynophagia, aspiration pneumonia, non-aspiration pneumonia, reflux, esophageal injury, and esophagitis.</description>
        <time_frame>Assessed over 36 hours of treatment and up to 30 days of follow-up.</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intervention</title>
          <description>The placement of the Esophageal Cooling Device will follow standard recommendations as per Instructions for Use. The Esophageal Cooling Device will be connected to the appropriate console (Meditherm III, Blanketrol II, or Blanketrol III).&#xD;
Esophageal Cooling Device (ECD), manufactured by Advanced Cooling Therapy, Inc.: Use of the Esophageal Cooling Device for control of patient temperature. Adverse events specifically monitored included the following: cardiac arrhythmias, severe bradycardia, myocardial infarction/reinfarction, dysphagia, odynophagia, aspiration pneumonia, nonaspiration pneumonia, reflux, esophageal injury, and esophagitis.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>a small volume left hydrothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alexander Tsarev</name_or_title>
      <organization>Department of Anesthesiology &amp; Intensive Care Medicine, Dnipropetrovsk Medical Academy</organization>
      <phone>+38 057 701 52 00</phone>
      <email>tsarev03@rambler.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

